Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
Local drugmakers, including Sun Pharma, Biocon, Zydus, Cipla, and Dr. Reddy’s are racing to develop cheaper versions of semaglutide as its Indian patent nears expiry.
Eli Lilly’s first quarter saw rapid revenue growth, but the market responded negatively due to profit shortfalls and emerging competitive pressures. Management credited the surge in sales to the continued success of its diabetes and obesity medicines, particularly Mounjaro and Zepbound, which now account for a significant portion of total revenue. However, executives also acknowledged that higher marketing and R&D spending, as well as elevated costs tied to launching new products and acquiring late-stage assets, weighed on profitability. CEO Dave Ricks noted that the company is facing “a lot of investor focus right now on tariffs and trade,” while CFO Lucas Montarce cited a “26% increase in marketing, selling and administrative expenses” as Lilly ramped up promotion for new launches.
GLP-1 obesity drug use is rising, but long-term adherence remains low. While one-year persistence has improved in 2024, only 8.1% stayed on therapy for three years.
HIMS CEO said that the pharma company’s commercial team has been increasingly pressuring the company to control clinical standards and steer patients to Wegovy regardless of whether it is clinically best for patients.
Novo Nordisk's CagriSema achieved significant weight loss in phase 3 trials, though safety concerns may limit its edge over existing and pipeline rivals.
Sciwind Biosciences is expanding its global footprint with licensing deals and early talks for overseas development, as it eyes a double-digit market share in China's fast-growing obesity drug sector.
Efsitora matched or exceeded A1C reductions seen with daily basal insulin across three trials, while orforglipron demonstrated benefits for blood sugar control and weight loss at higher doses.
